CLL cells were maintained in RPMI 1640 medium supplemented with 10% FBS, 2 mM Lglutamine, and 100 U/mL of penicillin and 100 μg/mL of streptomycin at 37 °C in an atmosphere containing 5% CO2.
CXCR4 phenotyping in primary CLL samples and cell lines
The phenotyping of CLL cells for CXCR4 expression was carried out by flow cytometry using a 1:200 dilution of PE mouse anti-human CD184 Antibody (Catalog # 555974, BD Biosciences).
The isotypic control was PE mouse IgG2a, k isotype control (Catalog # 555574, BD Biosciences).
CXCL12 phenotyping in primary CLL samples and cell lines
CXCL12 does not harbor any transmembrane domains, but does contain a signal peptide motif that can be detected as a secreted protein. To evaluate CXCL12 expression we did intracellular staining using the Cytofix/Cytoperm kit (Catalog # 51-2090KZ, BD Biosciences, San Diego, CA). The samples were washed with BD Perm/Wash buffer (Catalog # 51-2091KZ, BD Biosciences, San Diego, CA) and incubated for 30 minutes at room temperature with a 1:100 dilution of anti-CXCL12-APC tagged antibody (Catalog #IC350A, R&D System). The samples were then washed twice with FACS buffer (phosphate buffered saline containing 0.5% BSA plus 0.1% NaN 3 ) and analyzed by flow cytometry. APC-mouse IgG1k (Catalog # 555751, BD Biosciences) was used as an isotype control with a dilution of 1:100.
CXCR4 binding assays

Iodination of Ulocuplumab (BMS-936564) for scatchard analysis
Ulocuplumab (BMS-936564) was radioiodinated using IODO-GEN® solid phase iodination reagent (1,3,4,6-tetrachloro-3a-6a-diphenylglycouril; Pierce). Excess iodide was removed using a desalting column. Fractions of labeled antibody were collected and analyzed for radioactivity on a Wizard 1470 gamma counter (PerkinElmer). Radiopurity was established by thin layer chromatography of peak protein and radioactive fractions (Catalog # 15-005, Pinestar Technology). The 125 I-Ulocuplumab (BMS-936564) concentrations from the most radiopure fractions were measured in the Qubit™ Fluorometer (Invitrogen) using the Quant-iT™ reagent. A standard curve of counts per minute (CPM) corresponding to the molar concentration of 125 I-Ulocuplumab (BMS-936564) was plotted.
Affinity and saturation binding of 125 I-Ulocuplumab (BMS-936564)
Target cells were washed and adjusted to 8 x 10 6 cells/mL in binding buffer (24 mM Tris pH 7.2, 137 mM NaCl, 2.7 mM KCl, 2 mM glucose, 1 mM CaCl2, 1 mM MgCl2, 0.1% BSA).
Overnight buffer-coated (1% milk/PBS) glass fiber plates (Catalog # MAFBNOB50, Millipore) were washed 3 times with 0.2 mL of binding buffer. Fifty microliters of buffer alone was added to the maximum binding wells (total binding) and control wells. 25 µL of varying concentrations of 125 I-Ulocuplumab (BMS-936564) were added to all wells. 25 µL of varying concentrations of unlabeled antibody at 100-fold excess was added to control wells to determine nonspecific binding (NSB). 25 µL of cells suspended in binding buffer was added to all wells to bring the total volume to 50 µL. The plates were incubated for 2 hours at 4°C followed by three washes with 0.2 mL cold wash buffer (24 mM Tris pH 7.2, 500 mM NaCl, 2.7 mM KCl, 2 mM glucose, 1 mM CaCl2, 1 mM MgCl2, 0.1% BSA). Filters were removed and radioactivity was measured on a Wizard® gamma counter (PerkinElmer).
The CPM generated by the competition with unlabeled Ulocuplumab (BMS-936564) was 
CDC assay
Ramos target cells (5 x 10 4 cells/mL) were mixed with a 1:3 dilution of human complement (Catalog # A113, Quidel) and plated 50 μL/well in a 96-well plate. Ulocuplumab (BMS-936564) and isotype control antibody were serially diluted 5-fold from 50 μg/mL to 3.2 ng/mL and dispensed into the cell/complement mixture in duplicate. Assay plates were incubated at 37°C for 2 hours before the addition of alamarBlue (Catalog # DAL1100, Biosource). Alamar Blue is a redox indicator that yields a colorimetric change and a fluorescent signal in response to metabolic activity to measure cell viability. The plates were incubated for an additional 21 hours at 37°C and read on a Spectra Max Gemini fluorescent plate reader (Molecular Devices, Sunnyvale, CA; EX530 EM590). Viable cell count was considered proportional to fluorescence units (FLU) and was plotted against antibody concentration with a nonlinear regression analysis using GraphPad Prism software.
Flow Cytometry
The flow cytometric data collection and analysis was carried out using FACScalibur (BD Biosciences, San Jose, CA) and FlowJo software (version 9, TreeStar Inc, Ashland, OR). 
Detection of apoptosis
Inhibition of actin polymerization
The Ulocuplumab (BMS-936564) antibody was assessed for its ability to inhibit actin polymerization in primary leukemia cells from patients with CLL. Actin polymerization is a surrogate marker of cancer cell migration, metastatic potential and stromal cell dependency induced by the interaction of CXCR4 with CXCL12. 6 CLL cells were thawed and resuspended in RPMI-1640 medium with 0.5% BSA and allowed to rest for 1-2 hours 37°C. 
Inhibition of migration of cells in a transwell assay
Ulocuplumab (BMS-936564) was assessed for its ability to inhibit CXCL12 induced chemotaxis in primary leukemia cells from CLL patients using a transwell migration assay. 
Detection of reactive oxygen species (ROS) by flow cytometry
CLL cells were seeded at 2.5x10 5 /ml in RPMI media and treated with 10 g/ml of Ulocuplumab (BMS-936564) for 4 hours at 37°C and 5% CO2 in 24-well plates. The generation of ROS was detected using dihydroethidium (HE) staining (Catalog # D1168, Sigma-Aldrich, St. Louis, MO). HE is a cell-permeable fluorogenic probe that reacts with ROS to form ethidium, which intercalates within double-stranded DNA in the nucleus and emits red fluorescence. Cells were re-suspended in phosphate buffered saline (PBS) containing 2.5 M of HE dye and incubated for 30 minutes in the dark at room temperature.
Cells were then washed with annexin V binding buffer (AVB) (catalog # 51-66121E, BD Bioscience) twice and stained with a 1:100 dilution of annexin V (catalog # 556421, BD Biosciences) in AVB at room temperature for 15 minutes. The samples were then analyzed by flow cytometry followed by data analysis using FlowJo software. Further, to test whether ROS specificity, we used ROS inhibitor Tiron (Catalog # 172553, Sigma-Aldrich) at 30 mM concentration. The CLL cells were incubated with BMS-36564, rituximab, GA101, and F-ara-A in absence or presence of Tiron for 6 hrs. The CLL cells were assessed for ROS production by CD19/CD5/HE staining and cell death by CD19/CD5/Annexin-V staining followed by flow cytometry analysis.
